Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A2 in patients with stable angina

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 24, Issue 4, 2014, Pages 434-439

  Gajos, Grzegorz ^a,b   Zalewski, Jaroslaw ^a,b   Mostowik, Magdalena ^a,b   Konduracka, Ewa ^a,b   Nessler, Jadwiga ^a,b   Undas, Anetta ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

Atherosclerosis; Inflammation; Oxidative stress; Percutaneous coronary intervention; Polyunsaturated omega 3 fatty acids; Stable coronary disease

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; INTERLEUKIN 6; MYELOPEROXIDASE; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; AUTACOID; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN; PEROXIDASE; PLA2G7 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; VERY ELDERLY; ANGINA, STABLE; BLOOD; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DOWN REGULATION; DRUG EFFECTS; ENZYMOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLAND; TIME; TREATMENT OUTCOME;

ANGINA;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; ANGINA, STABLE; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DOWN-REGULATION; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PEROXIDASE; POLAND; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897084759     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2013.09.011     Document Type: Article

References (19)

1. 2 in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 2010, 122:2183-2200.
2. Thompson A., Gao P., Orfei L., Watson S., Di Angelantonio E., Kaptoge S., et al. Lp-PLA(2) studies collaboration, lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536-1544.
3. Nelson T.L., Hokanson J.E., Hickey M.S. Omega-3 fatty acids and lipoprotein associated phospholipase A(2) in healthy older adult males and females. Eur J Nutr 2011, 50:185-193.
4. Jawień J. Atherosclerosis in 2012: what is new?. Pol Arch Med Wewn 2012, 122:170-173.
5. De Caterina R. n-3 fatty acids in cardiovascular disease. N Engl J Med 2011, 364:2439-2450.
6. Rauch B., Schiele R., Schneider S., Diller F., Victor N., Gohlke H., et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010, 122:2152-2159.
7. Kromhout D., Giltay E.J., Geleijnse J.M., Alpha Omega Trial Group n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010, 363:2015-2026.
8. Gajos G. The fish oil story-back to Greenland?. Cardiology 2011, 118:245-247.
9. Gajos G., Rostoff P., Undas A., Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI study. J Am Coll Cardiol 2010, 55:1671-1678.
10. Gajos G., Zalewski J., Rostoff P., Nessler J., Piwowarska W., Undas A. Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). Arterioscler Thromb Vasc Biol 2011, 31:1696-1702.
11. Wang Q., Liang X., Wang L., Lu X., Huang J., Cao J., et al. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis 2012, 221:536-543. 10.
12. Opolski G., Strojek K., Kurzelewski M., Ostrowski M., Rabczenko D. Cardiovascular therapy, diagnostic procedures, and control of risk factors in patients with diabetes or coronary artery disease in Poland: the Kardia-Pol registry. Pol Arch Med Wewn 2012, 122:413-421.
13. Gajos G., Zalewski J., Nessler J., Zmudka K., Undas A., Piwowarska W. Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism. Kardiol Pol 2012, 70:439-445.
14. Pedersen M.W., Koenig W., Christensen J.H., Schmidt E.B. The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur J Nutr 2009, 48:1-5.
15. Schmidt E.B., Koenig W., Khuseyinova N., Christensen J.H. Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. Atherosclerosis 2008, 196:420-424.
16. Bouwens M., van de Rest O., Dellschaft N., Bromhaar M.G., deGroot L.C., Geleijnse J.M., et al. Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am J Clin Nutr 2009, 90:415-424.
17. Kris-Etherton P.M., Harris W.S., Appel L.J., American Heart Association, Nutrition Committee Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757.
18. Mitsios J.V., Vini M.P., Stengel D., Ninio E., Tselepis A.D. Human platelets secrete the plasma type of platelet-activating factor acetylhydrolase primarily associated with microparticles. Arterioscler Thromb Vasc Biol 2006, 26:1907-1913.
19. Nasopoulou C., Tsoupras A.B., Karantonis H.C., Demopoulos C.A., Zabetakis I. Fish polar lipids retard atherosclerosis in rabbits by down-regulating PAF biosynthesis and up-regulating PAF catabolism. Lipids Health Dis 2011, 10:213.